Van Cleef Asset Management Inc Has $567,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Van Cleef Asset Management Inc decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 10.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,246 shares of the biopharmaceutical company’s stock after selling 1,439 shares during the period. Van Cleef Asset Management Inc’s holdings in Bristol Myers Squibb were worth $567,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in BMY. AE Wealth Management LLC lifted its position in shares of Bristol Myers Squibb by 271.1% during the second quarter. AE Wealth Management LLC now owns 253,305 shares of the biopharmaceutical company’s stock worth $11,725,000 after purchasing an additional 185,045 shares in the last quarter. Stokes Family Office LLC increased its holdings in shares of Bristol Myers Squibb by 2.7% in the second quarter. Stokes Family Office LLC now owns 37,373 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 971 shares in the last quarter. Mark Sheptoff Financial Planning LLC raised its position in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares during the last quarter. Kinsale Capital Group Inc. lifted its holdings in Bristol Myers Squibb by 13.4% during the 2nd quarter. Kinsale Capital Group Inc. now owns 149,777 shares of the biopharmaceutical company’s stock worth $6,933,000 after buying an additional 17,687 shares in the last quarter. Finally, Wedbush Securities Inc. boosted its position in Bristol Myers Squibb by 2.4% in the 2nd quarter. Wedbush Securities Inc. now owns 56,957 shares of the biopharmaceutical company’s stock valued at $2,637,000 after buying an additional 1,353 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent research reports. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $46.74 on Friday. The stock has a market cap of $95.14 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The stock has a 50-day moving average of $45.25 and a 200-day moving average of $46.72. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter last year, the firm earned $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were given a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.